Table 3.
Change from baseline N-terminal-pro-B-type-natriuretic-peptide and risk of all-cause death, combined cardiovascular events, myocardial infarction, sudden death, and stroke
| Per cent change from baseline NT-pro-BNP (pg/mL) |
||||
|---|---|---|---|---|
| Decrease (less than −10%) (n = 428) | No change (−10 to 10%) (n = 160) | Increase (>10–100%) (n = 352) | Increase (>100%) (n = 263) | |
| All-cause death | ||||
| Number of events during study, n | 183 | 71 | 163 | 167 |
| Adjusted HRa (95% confidence interval) | 0.90 (0.68–1.19), P = 0.454 | —b | 0.99 (0.74–1.31), P = 0.931 | 1.46 (1.10–1.95), P = 0.009 |
| Adjusted HRa (95% confidence interval) with NT-pro-BNP as a continuous variable, 1.23 (1.14–1.34), P < 0.001 | ||||
| Combined cardiovascular endpoint (myocardial infarction, cardiac death, stroke) | ||||
| Number of events during study, n | 144 | 52 | 117 | 110 |
| Adjusted HRa (95% confidence interval) | 1.00 (0.72–1.38), P = 0.996 | —b | 0.98 (0.70–1.36), P = 0.898 | 1.37 (0.98–1.92), P = 0.068 |
| Adjusted HRa (95% confidence interval) with NT-pro-BNP as a continuous variable, 1.19 (1.07–1.32), P = 0.001 | ||||
| Sudden death | ||||
| Number of events during study, n | 39 | 23 | 37 | 53 |
| Adjusted HRa (95% confidence interval) | 0.61 (0.36–1.02), P = 0.060 | —b | 0.70 (0.42–1.19), P = 0.192 | 1.51 (0.91–2.51), P = 0.109 |
| Adjusted HRa (95% confidence interval) with NT-pro-BNP as a continuous variable, 1.45 (1.25–1.69), P < 0.001 | ||||
| Stroke | ||||
| Number of events during study, n | 32 | 12 | 26 | 18 |
| Adjusted HRa (95% confidence interval) | 0.88 (0.45–1.73), P = 0.706 | —b | 0.91 (0.45–1.83), P = 0.790 | 0.96 (0.45–2.02), P = 0.908 |
| Adjusted HRa (95% confidence interval) with NT-pro-BNP as a continuous variable, 1.10 ( 0.89–1.37), P = 0.391 | ||||
| Myocardial infarction | ||||
| Number of events during study, n | 69 | 19 | 51 | 41 |
| Adjusted HRa (95% confidence interval) | 1.30 (0.78–2.18), P = 0.319 | —b | 1.14 (0.69–1.95), P = 0.630 | 1.35 (0.77–2.36), P = 0.290 |
| Adjusted HRa (95% confidence interval) with NT-pro-BNP as a continuous variable, 1.08 ( 0.92–1.26), P = 0.380 | ||||
aAdjustment for gender, age, treatment, phosphate, low-density lipoprotein, haemoglobin, glycated haemoglobin, albumin, ever smoking, systolic/diastolic blood pressure, body mass index, ultrafiltration volume, duration of dialysis, AV fistula, history of stroke or transitory ischaemic attack, CAD (e.g. MI, coronary artery bypass grafting, percutaneous coronary intervention, and angiographically documented CAD), peripheral vascular disease, and CHF.
bThe group with no change (i.e. a change of −10 to 10%) was used as reference for each of the others.